STRATA™ select

Reading the Strata Oncology Testing Summary

Strata Select is a comprehensive treatment selection test providing pan-solid tumor molecular profiling and treatment response scores for immunotherapy and beyond.

The Strata Oncology Testing Summary included as the first page of every Strata Select report provides a consolidated view of patient results, plus expert commentary for context. All in one place.

1 Molecular Diagnosis
Pathologist assessment of most likely tumor type based on molecular features of the sample - invaluable in cases of Cancer of Unknown Primary

Pertinent Biomarker Summary

A summary of molecular findings from patient's tumor sample

2 Genomic Alterations
All prioritized genomic alterations, regardless of whether they are associated with approved or guideline-recommended therapies. When identified, probable germline mutations are also noted

3 Negative Genomic Alterations
All negative standard of care genes associated with a patient's tumor type

4 Genomic Signatures
HRD (ovarian only), TMB, and MSI results

5 Immunotherapy Response Score (IRS)
Results from Strata's pan-solid tumor predictive diagnostic tool for anti-PD-1/PD-L1 monotherapy benefit

6 Strata RNA Supplement Results
Section visible only when a tumor-type specific therapy association based on results in the Strata RNA Supplement (assays listed below) is present

- Gene Expression
- Antibody-drug Conjugate (ADC) Treatment Response Scores (TRSs)
- Angiogenesis inhibitor Treatment Response Score (TRS)

Therapy Associations

Concise table listing relevant biomarker results alongside associated therapies. Expanded context and data supporting therapy associations based on expert pathologist review are provided in a separate Therapy Rationale section

7 Biomarker Results
Result(s) with tumor type-specific therapy associations

8 Predicted Benefit
Predicted therapeutic benefit based on biomarker results

- **Benefit –** clinical benefit in patients with the indicated alteration(s) according to the level of evidence
- **Less Benefit –** less clinical benefit compared to unselected patients
- **Not Indicated –** biomarker contraindicates a standard of care therapy

9 Therapies
Therapies associated with identified biomarkers; superscripts 1/2/L/M denote line of therapy (first, second, later, maintenance); * denotes a NCCN preferred therapy

10 Evidence Level
Level of evidence supporting the predicted benefit of the listed therapy

1. FDA recognized
2. Standard of care biomarker recommended per NCCN
3. Compelling clinical evidence
4. Compelling biologic evidence

Strata Oncology Testing Summary

Patient MRN	Patient Name	Birth Date	Sex	Strata Case
---	---, ---	---	Female	---
Client Specimen ID	**Specimen Site**	**Part**	**Date of Collection**	**Date Received**
---	Omental Mass	---	---	---
Client		**Ordering Physician**		
---		---		

1 • Molecular Diagnosis and Tissue Specimen Information

Determined at time of testing

Cancer Type	Tumor Content
Ovarian Cancer	90%
Cancer Subtype	**Surface Area**
High-Grade Serous Ovarian Cancer	30mm^2

• Pertinent Biomarker Summary

	Strata Select	
2	Genomic Alterations	BRCA1 p.C1270_S1271delins* (79% VAF), MDM2 amplification (6 copies), TP53 p.S127F (88% VAF)
3	Negative Genomic Findings	BRAF, BRCA2, NTRK1, NTRK2, NTRK3, RET
4	Genomic Signatures	HRD Positive, Microsatellite Stable, TMB Low (3 muts/Mb)
5	Immunotherapy Response Score	IRS High
6	**Strata RNA Supplement**	
	Gene Expression	FOLR1 High

⚠ Germline Note. The germline/somatic status of the BRCA1 mutation is unclear and additional evaluation is recommended as clinically indicated; biallelic loss is present.

• Therapy Associations

7 Biomarker Results	8 Predicted Benefit	9 Therapies	10 Evidence Level
BRCA1 p.C1270_S1271delins*	Benefit	olaparib, niraparib, rucaparib [M*,L]	1
FOLR1 High	Benefit	mirvetuximab soravtansine [2*, L*]	1
TMB Low, IRS High	Benefit	pembrolizumab, nivolumab, or atezolizumab [2, L]	3

Therapy Rationale. The PARP inhibitors olaparib, niraparib and rucaparib are NCCN recommended for maintenance therapy in patients with platinum sensitive ovarian cancer harboring germline or somatic BRCA1/2 mutations. The role of PARP inhibitors is less clear as maintenance therapy in patients who have received multiple lines of chemotherapy and no prior PARP inhibition, with NCCN recommending olaparib regardless of BRCA1/2 mutation status, and niraparib and rucaparib only in those with deleterious or

Questions? Our Medical Affairs team is available to discuss any general questions about Strata Select or the Strata Oncology Testing Summary, as well as to consult on individual patient reports. Please reach out to medical.affairs@strataoncology.com

STRATA oncology